The international postgraduate ULG Health Outcome Research jointly organized by VSCR and SFU took place from 15.11-18.11.18 at the Sigmund Freud University Vienna.
There were postgraduate students from 10 different countries (Austria, Germany, Czech Republic, Latvia, United Arab Emirates, Nepal, Iran, Norway, Serbia and Poland).
The professors and lecturers came from Austria, Switzerland, Germany, Belgium, Hungary.
The language of instruction was English.
The key note lecture on how to define innovation was given by Suerie Moon, Harvard University, Boston, MPA, PhD, followed by a public panel discussion with national and international stakeholders.
The repetition of this module Evidence-Based Decision Making for Pricing and Reimbursement will take place from 27 to 29 May 2019 and later in October 2019.
VSCR-SFU University Course Health Outcome Research
Opening Key Note Lecture and Panel Discussion
Key note lecture: HOW TO DEFINE INNOVATION?
RESPONSE FROM INDUSTRY AND LESSONS LEARNED
Panel Discussion – Value and Price of Innovation in Pharmaceuticals and Devices
left to right – Dr. Vladimir Kopernicky, Vice President, International Medical Affairs, Eli Lilly
DrDr. Wolfgang Wein, General Manager Merck Austria
Dr. Sylvia Nanz, Medical Director Pfizer Austria
Priv.-Doz. Dr. phil. Claudia Wild, Director of Ludwig Boltzmann Institut, HTA
Univ. Prof. Dr. Heinrich Kelch, CEO VSCR
Dr. Anna Bucsics, Former Department Head, Department of Pharmaceutical Affairs, Federation of Austrian Social Insurance Institutions
Dr. Martin Gleitsmann, Head of Department of Social Policy and Health, Austrian Federal Economic Chamber
Univ.-Prof. Dr. Ernst Agneter, MBA, Executive Board of Association of the Austrian Pharmaceutical Industry, Chairman of the Pharmig working group Health Economics & Reimbursement